28 results on '"Yassin, Aksam"'
Search Results
2. PREDIABETES, HYPOGONADISM & ERECTILE DYSFUNCTION: GLYCAEMIC CONTROL IN 109 HYPOGONADAL MEN TREATED WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) FOR UP TO 8 YEARS: REAL-LIFE DATA FROM REGISTRY STUDIES: MP47-07
3. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men
4. PD45-06 LONG-TERM EFFECTS ON ERECTILE FUNCTION UPON TREATMENT UP TO 11 YEARS WITH TESTOSTERONE UNDECANOATE INJECTIONS (TU) IN HYPOGONADAL MEN WITH TYPE 2 DIABETES MELLITUS (T2DM): REAL-LIFE DATA FROM AN OBSERVATIONAL REGISTRY STUDY
5. MP27-03 EFFECTS OF CONTINUOUS LONG-TERM TESTOSTERONE REPLACEMENT THERAPY (TRT) UP TO 11 YEARS IN 115 HYPOGONADAL ELDERLY MEN ON ANTHROPOMETRIC, ENDOCRINE AND METABOLIC PARAMETERS: REAL-LIFE EXPERIENCE FROM AN OBSERVATIONAL REGISTRY STUDY
6. Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries
7. Long-Term Testosterone Treatment in Elderly Men with Hypogonadism and Erectile Dysfunction Reduces Obesity Parameters and Improves Metabolic Syndrome and Health-Related Quality of Life
8. LONG-TERM TESTOSTERONE TREATMENT LEADS TO PROGRESSIVE WEIGHT LOSS AND WAIST SIZE REDUCTION IN HYPOGONADAL MEN: MP48-01
9. 162 HYPOGONADAL MEN WITH OBESITY RESPOND TO LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE WITH UNEXPECTED WEIGHT LOSS: MP32-17
10. TESTOSTERONE REPLACEMENT THERAPY IMPROVES THE QUALITY OF LIFE OF HYPOGONADAL MEN DIAGNOSED WITH “LATE ONSET HYPOGONADISM” – ASSESSED BY VALIDATED QUESTIONNAIRES: MP32-18
11. COMPLETING FIVE YEARS OF TESTOSTERONE TREATMENT LEADS TO PROGRESSIVE WEIGHT LOSS AND WAIST SIZE REDUCTION AS WELL AS IMPROVEMENT OF METABOLIC SYNDROME PARAMETERS IN MEN WITH LATE ONSET HYPOGONADISM (LOH): MP32-12
12. Combined Testosterone and Vardenafil Treatment for Restoring Erectile Function in Hypogonadal Patients who Failed to Respond to Testosterone Therapy Alone
13. EFFECTS OF LONG-TERM TREATMENT WITH TESTOSTERONE UNDECANOATE INJECTIONS IN HYPOGONADAL MEN ON WAIST CIRCUMFERENCE, BODY WEIGHT AND BMI: 1400
14. Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study)
15. Endocrine Aspects of Male Sexual Dysfunctions
16. FROM WHICH SERUM TESTOSTERONE LEVEL SHOULD WE ADD TESTOSTERONE THERAPY TO MEN WITH ERECTILE DYSFUNCTION NOT RESPONDING TO PDE5 INHIBITORS ALONE? A DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF TESTOSTERONE GEL ADDITION TO MEN NOT RESPONDING TO TADALAFIL ONCE A DAY ALONE: 1367
17. FROM WHICH SERUM TESTOSTERONE LEVEL SHOULD WE ADD TESTOSTERONE THERAPY TO MEN WITH ERECTILE DYSFUNCTION NOT RESPONDING TO PDE5 INHIBITORS ALONE? A DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF TESTOSTERONE GEL ADDITION TO MEN NOT RESPONDING TO TADALAFIL ONCE A DAY ALONE: 1367
18. FRACTURE OF PENIS: REVIEW, ANALYSES AND TREATMENT OUTCOMES OF 26 CASES: 10
19. RIGISCAN MONITORING OF NOCTURNAL TUMESCENCE IN PATIENTS WITH LOW TESTOSTERONE LEVEL TREATED WITH TESTOSTERONE UNDECANOATE: 06
20. THE LINK BETWEEN ERECTILE DYSFUNCTION, METABOLIC SYNDROME AND TESTOSTERONE DEFICIENCY: OUTCOME OF DATA ANALYSES OF 771 ED PATIENTS: 03
21. TESTOSTERONE TREATMENT IN HYPOGONADAL PATIENTS DOES NOT CAUSE HIGHER INCIDENCE OF PROSTATE CANCER: 870
22. Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction
23. More than eight yearsʼ hands-on experience with the novel long-acting parenteral testosterone undecanoate
24. Long-acting testosterone undecanoate for parenteral testosterone therapy
25. Testosterone replacement in symptomatic aging males is safe and effective: DB-3˙1
26. Efficacy and Safety of Flexible-Dose Vardenafil in Men with Type 1 Diabetes and Erectile Dysfunction
27. Testosterone Undecanoate Restores Erectile Function in a Subset of Patients with Venous Leakage: A Series of Case Reports
28. Safety and Efficacy of Vardenafil, a Selective Phosphodiesterase 5 Inhibitor, in Patients with Erectile Dysfunction and Arterial Hypertension Treated with Multiple Antihypertensives
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.